MedPath

Treatment Study Comparing Medium or High Dose Uva-1 Treatment 3x/Week Versus Fluocinonide 0.05% Cream in the Treatment of Morphea.

Not Applicable
Completed
Conditions
Symmetric Limited Morphea
Registration Number
NCT00812188
Lead Sponsor
University of Texas Southwestern Medical Center
Brief Summary

Compare UVA-1 phototherapy treatment to topical steroid treatment in subjects with morphea.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
24
Inclusion Criteria
  • Male and female subjects 18 years of age or older.
  • Symmetric limited morphea.
Exclusion Criteria
  • Known sensitivity to fluocinonide 0.05% cream.
  • Clinical evidence of superinfected skin.
  • Immunocompromised state (including previously documented HIV).
  • Generalized Scleroderma.
  • Previous history of skin cancer.
  • Non-English speaking subjects.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Efficacy of UVA-1 treatment vs. topical steroid.5 years
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

UT Southwestern Medical Center at Dallas - Department of Dermatology Clinical Trials

🇺🇸

Dallas, Texas, United States

UT Southwestern Medical Center at Dallas - Department of Dermatology Clinical Trials
🇺🇸Dallas, Texas, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.